Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa

Diagnostic Microbiology and Infectious Disease

Volumn 72, Issue 3, 2012, Pages 258-262

  Hagihara, Mao ^a,b   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Carbapenems; Cross susceptibility; Doripenem; Surrogates; Susceptibility

Indexed keywords

DORIPENEM; IMIPENEM; MEROPENEM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REFERENCE STANDARDS; THIENAMYCINS;

EID: 84856590539     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.11.011     Document Type: Article

References (9)

1. Performance standards for antimicrobial susceptibility testing: 18th information supplement (M100-S18) 2008, Clinical and Laboratory Standards Institute (CLSI), CLSI, Wayne, PA.
2. Performance standards for antimicrobial susceptibility testing: 19th information supplement (M100-S19) 2009, Clinical and Laboratory Standards Institute (CLSI), CLSI, Wayne, PA.
3. Davies T.A., Shang W., Bush K., Flamm R.K. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2008, 52:1510-1512.
4. Eagye K.J., Banevicius M.A., Nicolau D.P. Pseudomonas aeruginosa: not just in the ICU anymore. Implications for empiric therapy (abstract #752) 2011.
5. Jones R.N., Pfaller M.A. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-99). Diagn. Microbiol. Infect. Dis. 2001, 39:237-243. SENTRY Antimicrobial Surveillance Program Participants Group (USA).
6. Jones R.N., Huynh H.K., Biedenbach D.J., Fritsche T.R., Sader H.S. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. 2004, 54:144-154.
7. Jones R.N., Sader H.S., Fritsche T.R., Janechek M.J. Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn. Microbiol. Infect. Dis. 2007, 59:467-472.
8. Mushtaq S., Ge Y., Livermore D.M. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 2004, 48:3086-3092.
9. Nicasio A.M., Kuti J.L., Nicolau D.P. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy 2008, 28:235-249.